Advaxis

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.

ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Advaxis headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Health Diagnostics sector. The company focuses on Biotechnology and has secured $24.4B in funding across 156 round(s). With a team of 51-100 employees, Advaxis is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Advaxis, raised $4.5M. Discover more about their projects, partnerships, and impact on our platform.